Recent

% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

  • hwmccusker hwmccusker Aug 9, 2013 7:49 AM Flag

    Beats on revenue with a smaller net loss than expected while expenses range up and down due to the discontinued operations

    The Bottom Line: The operations are smoother but need focus to cost containment but clinical costs are on target. A cleaner version of the NBS should be better and forth-coming as Q3/13 unfolds! Equity based compensation as related to specific units should be consolidated as even I am confused! AMR-o1 advances as do … other subsidiary endeavors with a leaner focus of results and expectation. Cash position isn’t bad considering other comparable entities. As the 2nd half unfolds … I expect greater specificity and metrics to evolve making measureable results more attuned to financial and trial expectations!

    NBS closed DOWN -$0.10 or -1.35% to $7.30 with 306 K volume on 8/8/13 from $7.40 with 297.7 K volume on 8/7/13 and after being UP +$0.46 to $7.75 with 620.5 K on 8/6/13. Not so bad, considering the reverse and subsequent listing on the NASDAQ. . Most comparable companies in the RegMed universe are trading DOWN post earnings release – I would foresee a smaller discount to the current pricing but … notice an appreciation focus to the stock as the anticipation was marginalized by events, share pricing, volume and attraction of industry named additions to the management team and hopefully … a new CFO soon.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NBS
2.250.00(0.00%)Jun 5 3:59 PMEDT